Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07815223) titled 'A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC' on Sept. 7.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Yantai Yuhuangding Hospital

Condition: SCLC, Limited Stage

Intervention: Drug: Tislelizumab + Anlotinib

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: November 4, 2025

Target Sample Size: 20

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07815223

Publish...